Sai Parenteral's Limited (NSE: SAIPARENT, BSE: 544742) is a Hyderabad, Telangana-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹2,235 Cr, it ranks #1,193 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹506.40 (as of 16 Nov 2026), the share price is 28.3% below its 52-week high of ₹706.00 and 26.6% above its 52-week low of ₹400.00.
| Current Price | ₹506.40 |
|---|---|
| Market Cap | ₹2,235 Cr |
| NSE Symbol | SAIPARENT |
| BSE Code | 544742 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 115.8 |
| Return on Equity | 2.88% |
| Return on Assets | 1.97% |
| 52-Week Range | ₹400.00 – ₹706.00 |
| 3-Month Price Change | -11.8% |
| Beta (1Y) | 0.6 |
| Headquarters | Hyderabad, Telangana |
| Website | www.saiparenterals.com |
| Revenue | ₹195 Cr |
|---|---|
| Net Profit | ₹11 Cr |
| Net Margin | 5.4% |
| EPS (Basic) | ₹2.38 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sai Parenteral's Limited reported revenue of ₹195 Cr in Q2 FY27, up 9.1% from ₹179 Cr in Q1 FY27. It posted a net profit of ₹11 Cr for the quarter, against a net profit of ₹8 Cr in Q1 FY27 (up 32.7%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹96 Cr (Q3 FY26) to ₹198 Cr (Q4 FY26). The company reported a net loss in 1 of these 4 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹195 Cr | ₹11 Cr | 5.4% |
| Q1 FY27 | ₹179 Cr | ₹8 Cr | 4.4% |
| Q4 FY26 | ₹198 Cr | ₹13 Cr | 6.6% |
| Q3 FY26 | ₹96 Cr | −₹7 Cr | −6.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.16% of Sai Parenteral's Limited's shares as of Sept 2026, unchanged from Mar 2026. Delivery averaged 50.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments. The company was founded in 1988 and is based in Hyderabad, India.
1. Branded Generic Formulations-This segment manufactures and sell generic formulations pharmaceutical products. 2. CDMO Products and Services-This segment engages in designing and developing pharmaceutical products, validation batches, such as trial runs conducted to ensure consistent manufacturing quality, stability studies, which assess drug performance under various conditions, dossier compilation, which involves preparing and compiling documents required for product approvals. 3. NA-NA 4. NA-NA
1. Branded Generic Formulations-37% 2. CDMO Products and Services-63%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Sai Parenteral's Limited is trading at ₹506.40, with a market capitalisation of ₹2,235 Cr.
Sai Parenteral's Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Sai Parenteral's Limited has a P/E of 115.8 and a return on equity of 2.88%.
Sai Parenteral's Limited is listed on the NSE under the symbol SAIPARENT and on the BSE under the scrip code 544742.
In Q2 FY27, Sai Parenteral's Limited reported revenue of ₹195 Cr and net profit of ₹11 Cr, with basic EPS of ₹2.38 (consolidated, parsed from the company's exchange filing).
Promoters held 51.16% of Sai Parenteral's Limited's shares as of Sept 2026, unchanged from Mar 2026.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.